Show simple item record

dc.contributor.authorPérez-Cabezas, Begoña
dc.contributor.authorCecílio, Pedro
dc.contributor.authorRobalo, Ana Luisa
dc.contributor.authorSilvestre, Ricardo
dc.contributor.authorCarrillo, Eugenia 
dc.contributor.authorMoreno, Javier 
dc.contributor.authorSan Martín, Juan Víctor
dc.contributor.authorVasconcellos, Rita
dc.contributor.authorCordeiro-da-Silva, Anabela
dc.date.accessioned2020-01-29T11:44:05Z
dc.date.available2020-01-29T11:44:05Z
dc.date.issued2016
dc.identifier.citationFront Immunol. 2016 Nov 4;7:478. eCollection 2016.es_ES
dc.identifier.issn1664-3224es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8960
dc.description.abstractThe complexity of Leishmania-host interactions, one of the main leishmaniasis issues, is yet to be fully understood. We detected elevated IL-27 plasma levels in European patients with active visceral disease caused by Leishmania infantum, which returned to basal levels after successful treatment, suggesting this cytokine as a probable infection mediator. We further addressed this hypothesis recurring to two classical susceptible visceral leishmaniasis mouse models. BALB/c, but not C57BL/6 mice, showed increased IL-27 systemic levels after infection, which was associated with an upregulation of IL-27p28 expression by dendritic cells and higher parasite burdens. Neutralization of IL-27 in acutely infected BALB/c led to decreased parasite burdens and a transient increase in IFN-γ+ splenic T cells, while administration of IL-27 to C57BL/6 promoted a local anti-inflammatory cytokine response at the site of infection and increased parasite loads. Overall, we show that, as in humans, BALB/c IL-27 systemic levels are infection dependently upregulated and may favor parasite installation by controlling inflammation.es_ES
dc.description.sponsorshipThis work was supported by Fundação para a Ciência e Tecnologia (FCT)/Ministério da Educação e da Ciência (MEC), co-funded by FEDER under the PT2020 Partnership Agreement through the Research Unit NO. 4293; by European Community’s Seventh Framework Programme under grant agreement No. 603182 (Project MuLeVaClin) and by the ISCIII-AES project (project reference PI13/00440). PC and BP-C are supported by fellowships from the European Community’s Seventh Framework Programme under grant agreements No. 603182 (Project MuLeVaClin) and No. 603240-2 (Project NMTryPI), respectively.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectIL-27es_ES
dc.subjectLeishmania infantumes_ES
dc.subjecthumanes_ES
dc.subjectimmune regulationes_ES
dc.subjectmouse modelses_ES
dc.titleInterleukin-27 Early Impacts Leishmania infantum Infection in Mice and Correlates with Active Visceral Disease in Humanses_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID27867384es_ES
dc.format.volume7es_ES
dc.format.page478es_ES
dc.identifier.doi10.3389/fimmu.2016.00478es_ES
dc.contributor.funderFundação para a Ciência e a Tecnologia (Portugal)es_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.contributor.funderEuropean Commissiones_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2016.00478es_ES
dc.identifier.journalFrontiers in immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI13/00440es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/Seventh Framework No. 603182es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/ PI13/00440es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional